DUBLIN, December 27, 2013 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/3zf33c/erectile) have announced the addition of the "Global Erectile Dysfunction Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering.
Erectile dysfunction (ED) is the inability to achieve or maintain satisfactory erection of penis during sexual intercourse. It is usually an age related condition but can also be triggered by psychological factors. It may occur due to various reasons such as smoking, sedentary lifestyle and administration of certain drugs such as antidepressants, psychotropic drugs, antihypertensive and recreational drugs.
Presently, oral phosphodiesterase type 5 inhibitors (PDE 5) commonly form the first line of treatment prescribed by doctors for ED. These include drugs namely, Viagra (sildenafil citrate), Cialis (tadalafil), Levitra/Staxyn (vardenafil), Stendra/Spedra (avanafil) and Zydena (udenafil). The demand for erectile dysfunction drugs is high and is continuously rising as it caters to the needs of the growing elderly population and the high incidence rates of chronic disorders comprising hypertension, renal diseases and diabetes, neurological disorders and hormonal insufficiencies.
This report studies the global erectile dysfunction drugs market with a major focus on the branded drugs which include Viagra (sildenafil citrate), Cialis (tadalafil), Levitra/Staxyn (vardenafil), Stendra/Spedra (avanafil), Zydena (udenafil) and others such as MUSE (Medicated Urethral System for Erections), Mvix and Helleva.
Pipeline analysis for drugs namely, Vitaros (alprostadil), Uprima (apomorphine) and others have also been included in the report. Market size and forecasts for the period 2010 - 2019 have been provided for each of the drugs, in terms of USD million, considering historical data for 2010 and 2011, and base year as 2012. The % compounded annual growth rate (CAGR) for each market segment for the forecast period 2013 - 2019 has also been provided along with market size estimations.
Key Topics Covered:
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
1.4 List of Abbreviations
2 Executive Summary
3 Market Overview
3.1 Introduction to Erectile Dysfunction
3.2 Current Market Trends and Future Outlook
3.3 Types of Treatments for ED
3.4 Market Drivers
3.5 Market Restraints
3.6 Market Opportunities
3.7 Porter's Five Forces Analysis: Global Erectile Dysfunction Drugs Market
3.8 Market Attractiveness Analysis: Global Erectile Dysfunction Drugs Market, By Geography (2015)
4 Global Erectile Dysfunction Drugs Market Revenue, By Brand, 2011-2019 (USD Million)
4.1 Market Overview
4.2 Viagra (Sildenafil Citrate)
4.3 Cialis (Tadalafil)
4.4 Levitra/Staxyn (Vardenafil)
4.5 Stendra/Spedra (Avanafil)
4.6 Zydena (Udenafil)
4.7 MUSE (Medicated Urethral System for Erection)
4.8 Mvix (Mirodenafil)
4.9 Helleva (Lodenafil Carbonate)
5 Global Erectile Dysfunction Drugs Market, Pipeline Analysis
5.2 Vitaros (Alprostadil)
5.3 Uprima (Apomorphine)
5.4 Others (Topiglan, Melanocortin Activators, Gene Therapy)
6 Global Erectile Dysfunction Drugs Market, By Geography
6.2 North America
6.5 Rest of the World (Row)
7 Competitive Landscape
7.1 Market Share Analysis: Global Erectile Dysfunction Drugs Market, 2012 (%)
8.1 Novel Drug Formulations and Genericization owing to Patent Expiration of well recognized ED Drugs
8.2 Mergers and Acquisitions to Strengthen Market Presence
8.3 Cost Containment Measures
9 Company Profiles
For more information visit http://www.researchandmarkets.com/research/3zf33c/erectile
Media Contact: Laura Wood, +353-1-481-1716, email@example.com
|SOURCE Research and Markets|
Copyright©2012 PR Newswire.
All rights reserved